Pharmacolog signs a collaboration agreement with researchers at Uppsala University regarding antibiotic treatment

Pharmacolog AB has entered a research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood during treatment of patients with severe infections.

Antibiotic treatment with the right dose is crucial for patients to survive severe infections. Today, technology is lacking to quickly determine blood concentrations of antibiotics in patients treated for serious infections. The collaboration between Pharmacolog AB and Professor Miklos Lipcsey at the Department of Surgical Sciences and Professor Anders Larsson at the Department of Medical Sciences, both at Uppsala University, is a result of preparatory tests of the ability to measure the antibiotic concentration in blood with Pharmacolog’s current technology. The collaboration will continue until December 2017 with the aim of developing a method for rapidly and patiently determining blood levels of antibiotics in patients treated for severe infections.

Hans Dahlin, Founder and Research Director at Pharmacolog: “I am extremely pleased that after a time of preliminary tests we can start this important research project with two outstanding experts on antibiotic treatment of severe infections. The project is well within our vision of participating in research projects that can lead to the development of new products for patient-controlled controls of intravenous drug treatments of severe diseases such as sepsis and cancer.”

Dr. Miklos Lipcsey, anesthetist and researcher Academic Hospital: “Healthcare is facing major challenges regarding the use of antibiotics. The correct dose is necessary to cure difficult infections but also a prerequisite for preventing resistance development. The research collaboration with Pharmacolog is very interesting given the great need for rapid analysis and measures in the treatment of antibiotics in severe infections. Several studies have shown that delayed or insufficient initial antibiotic treatment leads to significantly increased mortality in sepsis. We have already received some interesting promising results that we now hope through this project will result in scientific work that can contribute to new products for safer and more patient-adapted antibiotic treatment.”

 

Pharmacolog kallar till bolagsstämma

Aktieägarna i Pharmacolog i Uppsala AB (publ), org.nr 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.

Anmälan m.m.

Aktieägare som önskar delta vid årsstämman skall:

–    dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och

–    dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till mats.hogberg@pharmacolog.se.

Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (ell...

Continued negotiations with international MedTech Group

In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.

The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quar...

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...

Study in Lille completed

The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.

The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially result...